"The EMA has recommended restricting the use of the chikungunya vaccine for individuals over 65 after serious adverse events were reported, raising safety concerns."
"Despite initial approval a year ago, the EMA has identified serious adverse effects linked to the vaccine in older populations, prompting a temporary restriction."
The European Medicines Agency (EMA) has recommended a restriction on the chikungunya vaccine, Ixchiq, for people aged over 65 amid safety concerns from serious adverse events, including two fatalities. Despite its earlier approval, the EMA's investigation found a possible link between the vaccine and severe complications, particularly in older populations which were underrepresented in clinical trials. The agency emphasized the need for caution, highlighting that a causal relationship between the vaccination and adverse events remains unconfirmed. Similar restrictions have been adopted by the FDA, albeit with a lower age limit of 60.
Read at english.elpais.com
Unable to calculate read time
Collection
[
|
...
]